When Imbruvica (ibrutinib) stops working or resistance develops, there are several treatment paths that can be explored with a healthcare team. Here's a summary of the main options:
Other BTK Inhibitors
- Calquence (acalabrutinib) — a next-generation BTK inhibitor that may be better tolerated
- Pirtobrutinib — a newer, Show Full Answer
When Imbruvica (ibrutinib) stops working or resistance develops, there are several treatment paths that can be explored with a healthcare team. Here's a summary of the main options:
Other BTK Inhibitors:
- Calquence (acalabrutinib) — a next-generation BTK inhibitor that may be better tolerated
- Pirtobrutinib — a newer, more selective BTK inhibitor showing promising results in trials, including for people whose disease returned after earlier treatments
Targeted Therapies:
- Venclexta (venetoclax) — often used alone or combined with other drugs
- Gazyva (obinutuzumab) — targets proteins on B cells
- Rituxan (rituximab) — can be combined with other treatments
Chemotherapy Combinations:
- FCR (fludarabine, cyclophosphamide, rituximab)
- Bendamustine with rituximab
Bone Marrow Transplant:
- May be considered for younger patients with relapsed or refractory CLL who don't have major other health concerns It's also worth asking a doctor about clinical trials, which can open doors to cutting-edge treatments not yet widely available. Every situation is different, so working closely with a hematologist to find the best fit based on individual health history is really important.
September 3
Join
Your Privacy Choices
